BioSpace News Archive

KalVista Pharmaceuticals, Inc., announced that the compensation committee of KalVista’s board of directors granted one newly-hired employee inducement options to purchase an aggregate of 7,000 shares of KalVista common stock on April 1, 2022 as inducement material to such employee entering into employment with KalVista.

Castle Biosciences, Inc. today announced it has signed a definitive agreement to acquire AltheaDx, Inc.

Akebia Therapeutics, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted nine newly-hired employees options to purchase an aggregate of 53,000 shares of Akebia’s common stock on March 31, 2022, as inducements material to each such employee entering into employment with Akebia.

Fluidigm Corporation announced the closing of the previously announced strategic capital infusion from leading life sciences investors Casdin Capital, LLC and Viking Global Investors LP. Fluidigm has been renamed Standard BioTools Inc. and its common stock is expected to begin trading on Nasdaq under the symbol “LAB” as of the open of market on April 6, 2022.

Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a provider of products and technologies for surgical and chronic wound care dedicated to improving patient outcomes, announced today that it has closed the previously announced merger to acquire Precision Healing Inc.

Myomo, Inc. provides an update on the status of its joint venture (“JV”) in China and the associated impact on first quarter 2022 revenue.

Quanterix’ Simoa ® Technology Powers Large, International Comprehensive Reference Range Study Utilizing Serum Neurofilament Light (sNfL) to Assess Disease Activity in Multiple Sclerosis (MS) Patients.

Fairtility, the transparent AI innovator powering in vitro fertilization (IVF) for improved outcomes, announced the findings from its comprehensive study, Pseudo Contrastive Labeling for Predicting IVF Embryo Development Potential, published in Scientific Reports, a Nature Portfolio journal.

SCYNEXIS, Inc., a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, announced participation in three women’s health conferences in April.

Olympus, a global technology leader in designing and delivering innovative solutions for medical and surgical procedures, announced today a strategic distribution agreement with EndoClot® Plus, Inc. (EPI). EPI technologies complement Olympus’ leading portfolios in GI endoscopy and the company’s overall medtech strategy.